Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sven Poli MD

Sven Poli MD

Vice Chair, Department of Neurology, University Hospital Tübingen, Germany

Dr. Sven Poli is Professor of Neurology and Vice Medical Director of the Department of Neurology & Stroke at Tübingen University, Germany. His clinical expertise covers the broad spectrum of neurovascular disease ranging from prehospital management over neurocritical care to secondary stroke prevention. Since he was introduced to the field by Werner Hacke in 2006, he has been involved in clinical trials. He served as local principal investigator in more than 70 trials mainly with the indications ischemic stroke, intracranial hemorrhage, and cerebral venous thrombosis, and has been (co-)coordinating several (inter-)national projects such as ATTICUS (NCT02427126), PROOF (www.proof-trial.eu), REVISION (www.revision-trial.de) and APICES (www.apices-trial.de). He coauthored the German guidelines for secondary stroke prevention and is member of the European Stroke Organisation guideline board. Sven Poli has published over 200 articles in peer-reviewed journals of which 160 were original research articles.

Disclosures

Research support from BMS/Pfizer, Boehringer-Ingelheim, Daiichi Sankyo, European Union, German Federal Joint Committee Innovation Fund, and German Federal Ministry of Education and Research, Helena Laboratories and Werfen. Speakers’ honoraria/consulting fees from Alexion, AstraZeneca, Bayer, Boehringer-Ingelheim, BMS/Pfizer, Daiichi Sankyo, Portola, and Werfen.

Recent Contributions to PracticeUpdate:

  1. Apixaban vs Aspirin for Embolic Stroke of Undetermined Source